December 12, 2024 Clinical update on RVU120 Phase II program
Read More
December 5, 2024 Dosing of the first patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
Read More
December 2, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
December 2, 2024 Recommendation of Ryvu’s project for funding by the Małopolska Centre for Entrepreneurship
Read More
November 19, 2024 Publication dates for periodic reports in 2025
Read More
November 19, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
November 7, 2024 Ryvu Therapeutics Q3 2024 Financial Report
Read More
October 23, 2024 Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform presented at the 2024 EORTC-NCI-AACR Symposium
Read More
October 22, 2024 Conclusion of an agreement in the area of operational execution of MEN1703 (SEL24) Phase II clinical trial in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Read More
October 9, 2024 Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform to be presented at the 2024 EORTC-NCI-AACR Symposium
Read More
September 19, 2024 Dosing of the first patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Read More
September 11, 2024 Ryvu Therapeutics H1 2024 Financial Report
Read More
September 11, 2024 Continuation of the development of PRMT5 program
Read More
August 29, 2024 Fulfillment of conditions for the disbursement of the Tranche C of financing from the European Investment Bank
Read More
June 27, 2024 Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 27th, 2024
Read More
June 27, 2024 Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 19, 2024 Fulfillment of conditions for the disbursement of the Tranche B of financing from the European Investment Bank
Read More
June 14, 2024 Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Read More
June 14, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
June 4, 2024 Conclusion of funding agreement with the Polish Agency for Enterprise Development
Read More
Posts navigation
